By Fineline Cube 
Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced its financial results for the six months ended June 30, 2025, on August 7, 2025. The company reported revenue of $277.7 million, marking a 9% year-over-year decrease.
Business Segment Performance
- Oncology/Immunology Revenue: $143.5 million (H1 2024: $168.7 million), a 4% year-over-year decrease.
- Other Business Revenue: $134.2 million (H1 2024: $137.0 million), remaining relatively flat.
Key Product Sales
- FRUZAQLA (Fruquintinib): Sales increased to $43.1 million (H1 2024: $42.8 million). Takeda recorded market sales of $162.8 million, up 25%, driven by approvals in over 30 countries, including more than a dozen new markets in 2025. Future growth is expected from the new indication for FRUZAQLA in second-line endometrial cancer and its inclusion in key treatment guidelines.
- Sulanda (Surufatinib): Sales declined to $12.7 million (H1 2024: $25.4 million) due to competition from new somatostatin analog drugs. Efforts are underway to maintain market position through brand awareness and product differentiation.
- ORPATHYS (Savolitinib): Revenue decreased to $9.0 million (H1 2024: $13.1 million) with market sales of $15.2 million, affected by new competing drugs. Growth from the recent approval for EGFR TKI-refractory, MET-amplified non-small cell cancer is yet to be reflected.
- Tazemetostat: Revenue was $0.7 million (H1 2024: $0.5 million), primarily from sales in Hainan and Hong Kong. It was approved in March 2025 and launched in mainland China in July 2025.
Partner Collaboration Revenue
- Takeda: Upfront payments, regulatory milestone payments, and R&D service revenue totaled $29.5 million (H1 2024: $33.8 million), with $26.6 million recognized as revenue from Takeda’s deferred income.
- AstraZeneca: An $11.0 million milestone payment was received following the approval of the new drug application for the combination therapy of ORPATHYS with Tagrisso in China.
Full-Year Guidance Update
HutchMed has revised its full-year 2025 guidance for total oncology/immunology revenue to between $270 million and $350 million. This adjustment is mainly due to the deferral of milestone revenue from partners to 2026 and beyond, and the expected delay in the completion of the new drug application review for sovleplenib in China until after 2025.-Fineline Info & Tech